Drug Profile
PCAR 119
Alternative Names: PCAR 119Latest Information Update: 23 Feb 2022
Price :
$50
*
At a glance
- Originator PersonGen Biomedicine; PersonGen Biotherapeutics
- Developer PersonGen Biotherapeutics
- Class CAR-NK cell therapies; Cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Leukaemia; Lymphoma
Most Recent Events
- 23 Feb 2022 Discontinued - Phase-I/II for Leukaemia (In adolescents, In children, In the elderly, In adults) in China (IV) (PersonGen Biotherapeutics' pipeline, February 2022)
- 23 Feb 2022 Discontinued - Phase-I/II for Lymphoma (In adolescents, In children, In the elderly, In adults) in China (IV) (PersonGen Biotherapeutics' pipeline, February 2022)
- 01 Sep 2016 Phase-I/II clinical trials in Leukaemia (In children, In adolescents, In adults, In elderly) in China (IV) (NCT02892695)